Notify me when ABG Innovation Capital Partners III GP Ltd files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 1 | $64,532 | $0 | $0 | $0 | WHWK | 13F-HR | 17 Feb 2026, 17:13 |
| Q3 2025 | 1 | $50,665 | $0 | $0 | $0 | WHWK | 13F-HR | 14 Nov 2025, 16:23 |
| Q2 2025 | 1 | $49,865 | $0 | -$752,696 | -$752,696 | WHWK | 13F-HR | 14 Aug 2025, 16:40 |
| Q1 2025 | 3 | $800,161 | $0 | $0 | $0 | CSTL, WHWK, SYBX | 13F-HR | 15 May 2025, 11:12 |
| Q4 2024 | 3 | $1,082,657 | $0 | $0 | $0 | CSTL, AADI, SYBX | 13F-HR | 14 Feb 2025, 09:25 |
| Q3 2024 | 3 | $1,123,409 | $0 | $0 | $0 | CSTL, AADI, SYBX | 13F-HR | 14 Nov 2024, 07:30 |
| Q2 2024 | 3 | $859,505 | +$67,944 | $0 | +$67,944 | CSTL, AADI, SYBX | 13F-HR | 14 Aug 2024, 08:11 |
| Q1 2024 | 3 | $831,785 | $0 | -$69,130 | -$69,130 | CSTL, AADI, SYBX | 13F-HR | 15 May 2024, 07:09 |
| Q4 2023 | 3 | $899,714 | +$120,200 | -$38,572 | +$81,628 | CSTL, AADI, SYBX | 13F-HR | 14 Feb 2024, 07:20 |
| Q3 2023 | 3 | $735,578 | $0 | -$540,011 | -$540,011 | CSTL, AADI, SYBX | 13F-HR | 14 Nov 2023, 15:31 |
| Q2 2023 | 3 | $732,284 | $0 | $0 | $0 | CSTL, AADI, SYBX | 13F-HR | 14 Aug 2023, 16:23 |
| Q1 2023 | 3 | $1,087,178 | $0 | -$19,688 | -$19,688 | CSTL, AADI, SYBX | 13F-HR | 15 May 2023, 11:25 |
| Q4 2022 | 4 | $1,309,858 | $0 | -$4,000 | -$4,000 | CSTL, AADI, SYBX, IDRA | 13F-HR | 14 Feb 2023, 10:30 |
| Q3 2022 | 5 | $1,475,000 | $0 | -$8,000 | -$8,000 | CSTL, AADI, SYBX, IDRA, GNCA | 13F-HR | 14 Nov 2022, 07:34 |
| Q2 2022 | 6 | $1,344,000 | +$738,000 | $0 | +$738,000 | CSTL, AADI, SYBX, IDRA, NABRIVA THERAPEUTICS PLC | 13F-HR | 15 Aug 2022, 09:54 |
| Q1 2022 | 5 | $1,463,000 | $0 | -$93,000 | -$93,000 | SYBX, GNCA, AADI, IDRA, NABRIVA THERAPEUTICS PLC | 13F-HR | 16 May 2022, 06:51 |
| Q4 2021 | 6 | $1,729,000 | $0 | -$51,934 | -$51,934 | AADI, SYBX, GNCA, LUNG, IDRA | 13F-HR | 14 Feb 2022, 07:21 |
| Q3 2021 | 6 | $2,407,000 | +$783,000 | -$27,862,000 | -$27,079,000 | AADI, GNCA, SYBX, LUNG, IDRA | 13F-HR | 15 Nov 2021, 07:29 |
| Q2 2021 | 7 | $29,870,000 | +$27,186,000 | -$199,450,661 | -$172,264,661 | AVIR, GNCA, SYBX, ARPO, LUNG | 13F-HR | 16 Aug 2021, 08:30 |
| Q1 2021 | 7 | $203,504,000 | +$162,969,000 | -$110,265,000 | +$52,704,000 | ATEA PHARMACEUTICALS INC, LUNG, GNCA, SYBX, ARPO | 13F-HR | 17 May 2021, 07:41 |
| Q4 2020 | 7 | $169,844,000 | $0 | $0 | $0 | AVIR, LUNG, GNCA, SYBX, ARPO | 13F-HR | 16 Feb 2021, 07:29 |